<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "bevacizumab inj VIAL">
<dose><value>5</value>
<value>7.5</value>
<value>10</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>25 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
</frequency>
<instruction><value>DAY 1 of 14. Dilute dose in 100 mL 0.9% sodium chloride and administer over 10 minutes. (Maximum rate of administration is 0.5 mg/kg/minute.)</value>
<value>DAY 1 of 21. Dilute dose in 100 mL 0.9% sodium chloride and administer over 15 minutes. (Maximum rate of administration is 0.5 mg/kg/minute.)</value>
<value>DAY 1 of 14. Dilute dose in 100 mL 0.9% sodium chloride and administer over 20 minutes. (Maximum rate of administration is 0.5 mg/kg/minute.)</value>
</instruction>
<volume><value>16 mL</value>
<value>4 mL</value>
</volume>
<units><value>mg/kg</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>For monitoring / administration information, refer to CancerControl Alberta Bevacizumab (Avastin) Administration Guidelines.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3345</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions, Usage guidelines.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>